Semaglutide tabbas shine mafi inganci agonist GLP-1.
A halin yanzu, manyan magungunan asarar nauyi akan kasuwa sun haɗa da orlistat daga Roche, liraglutide daga Novo Nordisk da semaglutide.
Wegovy, analog na GLP-1 na Novo Nordisk, FDA ta amince da shi a cikin 2017 don kula da nau'in ciwon sukari na 2.A cikin Yuni 2021, FDA ta amince da alamar slimming na Wegovy.
A cikin 2022, farkon cikakkiyar kasuwancin shekara bayan lissafin Wegovy, Wegovy ya sami dala miliyan 877 a cikin alamun asarar nauyi.
Tare da jeri na semaglutide, kulawar subcutaneous sau ɗaya a mako ya inganta ingantaccen yarda da marasa lafiya, kuma tasirin asarar nauyi a bayyane yake.Sakamakon asarar nauyi a cikin makonni 68 shine 12.5% sama da wancan a cikin placebo (14.9% vs 2.4%), kuma ya zama samfurin tauraro a cikin kasuwar asarar nauyi na ɗan lokaci.
A cikin kwata na farko na 2023, Wegovy ya samu kudaden shiga na dalar Amurka miliyan 670, wanda ya karu da kashi 225% duk shekara.
Amincewa da alamar asarar nauyi na semaglutide ya dogara ne akan binciken lokaci na III da ake kira STEP.Nazarin STEP galibi yana kimanta tasirin warkewa na allurar subcutaneous na semaglutide 2.4mg sau ɗaya a mako idan aka kwatanta da placebo akan marasa lafiya masu kiba.
Binciken na STEP ya haɗa da gwaji da yawa, inda aka ɗauki kimanin 4,500 masu kiba ko manyan marasa lafiya, ciki har da:
Nazarin MATAKI 1 (taimakon sa kai na salon rayuwa) idan aka kwatanta da aminci na makonni 68 da ingancin allurar subcutaneous na semaglutide 2.4mg sau ɗaya a mako tare da placebo a cikin 1961 masu kiba ko manya.
Sakamakon ya nuna cewa matsakaicin canjin nauyin jiki shine 14.9% a cikin ƙungiyar semaglutide da 2.4% a cikin ƙungiyar PBO.Idan aka kwatanta da PBO, cututtukan gastrointestinal na semaglutide sun fi yawa, amma yawancin su suna da wucin gadi kuma suna iya raguwa ba tare da dakatar da tsarin kulawa na dindindin ba ko kuma sa marasa lafiya su janye daga binciken.Binciken STEP1 ya nuna cewa semaglutide yana da tasiri mai kyau na asarar nauyi akan marasa lafiya masu kiba.
Nazarin mataki na 2 (masu fama da kiba da nau'in ciwon sukari na 2) idan aka kwatanta aminci da ingancin allurar subcutaneous na semaglutide 2.4 MG sau ɗaya a mako tare da placebo da semaglutide 1.0mg a cikin 1210 masu kiba ko manya masu kiba na makonni 68.
Sakamakon ya nuna cewa matsakaicin nauyin nauyin jiki na ƙungiyoyin jiyya guda uku sun canza sosai, tare da -9.6% lokacin amfani da 2.4 MG na semaglutide, -7% lokacin amfani da 1.0mg na semaglutide, da -3.4% lokacin amfani da PBO.Binciken STEP2 ya nuna cewa semaglutide kuma yana nuna sakamako mai kyau na asarar nauyi ga marasa lafiya masu kiba da nau'in ciwon sukari na 2.
Nazarin STEP 3 (maganin halayyar adjuvant) idan aka kwatanta da 68-mako bambance-bambance a cikin aminci da inganci tsakanin allurar subcutaneous na semaglutide 2.4 MG sau ɗaya a mako da placebo hade tare da haɓakar halayyar halayyar a cikin 611 masu kiba ko manya.
A cikin makonni 8 na farko na binciken, duk batutuwa sun sami abinci mai maye gurbin abinci mai ƙarancin kalori da haɓakar ɗabi'a mai ƙarfi a cikin shirin 68-mako.Ana kuma buƙatar mahalarta suyi minti 100 na motsa jiki a kowane mako, tare da karuwa na minti 25 kowane mako hudu da iyakar minti 200 a kowane mako.
Sakamakon ya nuna cewa nauyin jikin marasa lafiya da aka yi amfani da su tare da semaglutide da kuma kula da halayyar halayyar ya ragu da 16% idan aka kwatanta da asali, yayin da na placebo kungiyar ya ragu da 5.7%.Daga bayanan STEP3, zamu iya ganin tasirin motsa jiki da abinci akan asarar nauyi, amma abin sha'awa, ƙarfafa salon rayuwa yana da ɗan tasiri akan ƙarfafa tasirin miyagun ƙwayoyi na semaglutide.
( Kwatanta ƙimar asarar nauyi tsakanin rukunin Semaglutide da rukunin Dulaglutide)
Magungunan na iya haɓaka metabolism na glucose ta hanyar haɓaka ƙwayoyin β pancreatic don ɓoye insulin;Kuma yana hana ƙwayoyin alpha na pancreatic ɓoye glucagon, don haka rage azumi da sukarin jini na postprandial.
(kwatanta nauyin jiki tsakanin ƙungiyar kula da Semaglutide da placebo)
Idan aka kwatanta da placebo, Semaglutide na iya rage haɗarin manyan abubuwan ƙarshen hadaddiyar giyar (mutuwar zuciya ta farko, infarction myocardial, bugun jini mara mutuwa) da 26%.Bayan shekaru 2 na jiyya, Semaglutide na iya rage haɗarin bugun jini mara mutuwa ta 39%, infarction na myocardial mara mutuwa ta 26% da mutuwar zuciya da jijiyoyin jini da 2%.Bugu da kari, yana iya rage cin abinci ta hanyar rage sha’awa da rage narkewar ciki, da kuma rage kitse a jiki, wanda ke taimakawa wajen rage kiba.
A cikin wannan binciken, an gano cewa phentermine-topiramate da GLP-1 agonist receptor agonist an tabbatar da su zama mafi kyawun magungunan asarar nauyi tsakanin manya da masu kiba.
